Immunome Doses First Patient in Phase 1 Trial of IM-1021, a ROR1-Targeted ADC [Yahoo! Finance]
Immunome, Inc. (IMNM)
Company Research
Source: Yahoo! Finance
best-in-class targeted cancer therapies, today announced that the first patient has been dosed in the Phase 1, first-in-human trial of IM-1021, a ROR1-targeted ADC. "Immunome is developing differentiated ADCs that we believe can greatly benefit cancer patients," said Bob Lechleider, M.D., Chief Medical Officer at Immunome. "The dosing of our first patient with IM-1021 advances that mission, as we work to establish safety and explore efficacy of IM-1021 in patients with high unmet need in B-cell lymphomas and solid tumors." IM-1021 is an optimized, ROR1-targeted ADC that incorporates Immunome's proprietary TOP1 inhibitor, HC74. The Phase 1 trial is an open-label, multicenter dose escalation and expansion study designed to determ
Read more
Impact Snapshot
Event Time:
IMNM
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IMNM alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IMNM alerts
High impacting Immunome, Inc. news events
Weekly update
A roundup of the hottest topics
IMNM
News
- Immunome to Present at the 24th Annual Needham Virtual Healthcare Conference [Yahoo! Finance]Yahoo! Finance
- Immunome to Present at the 24th Annual Needham Virtual Healthcare ConferenceBusiness Wire
- Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business Wire
- Immunome, Inc. (NASDAQ: IMNM) is now covered by analysts at Lake Street Capital. They set a "buy" rating and a $23.00 price target on the stock.MarketBeat
- Zentalis Pharmaceuticals Reports Full Year 2024 Financial Results and Operational Updates [Yahoo! Finance]Yahoo! Finance
IMNM
Earnings
- 11/13/24 - Miss
IMNM
Sec Filings
- 4/24/25 - Form ARS
- 4/24/25 - Form DEFA14A
- 4/24/25 - Form DEF
- IMNM's page on the SEC website